Laura Kolsi, PhD

Laura Kolsi is responsible for the DoA antigen conjugate production at Medix Biochemica Finland. Laura joined Medix Biochemica in 2020 through the acquisition of Biostride and was responsible for the production transfer of DoA antigen conjugate portfolio to Espoo, Finland. She holds a PhD degree in Medicinal Chemistry from University of Helsinki. In her PhD, she designed, synthesized and identified new small molecule natural product derivatives as potential compounds for targeting pancreatic cancer and inflammation in vitro. In addition, she developed sustainable and environmentally sound synthesis methods among diterpenoids chemistry. As a Technology Manager at Medix Biochemica, Laura Kolsi combines deep subject matter expertise with a strong commitment to customer success and sustainability. At the heart of her work is a drive to ensure that Medix Biochemica delivers well-performing, high-quality products that empower customers in their assay development.